| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/17/2003 | US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides |
| 07/17/2003 | US20030134424 For implanting/transfecting monodispersed silicon particles joined to DNA into target tissue, cell or the blood stream |
| 07/17/2003 | US20030134344 Her2 gene amplification as detected by fluorescence in situ hybridization |
| 07/17/2003 | US20030134319 Amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides |
| 07/17/2003 | US20030134308 Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| 07/17/2003 | US20030134027 Comprises pectin, alginate, calcium, and fiber; dietetics |
| 07/17/2003 | US20030133980 Biocompatible polymer blends and uses thereof |
| 07/17/2003 | US20030133973 Vesicle-forming lipid and a vesicle-forming lipid derivatized with a hydrophilic polymer |
| 07/17/2003 | US20030133951 Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 07/17/2003 | US20030133940 Medicaments for chemotherapeutic treatment of disease |
| 07/17/2003 | US20030133938 Antibody-avidin fusion proteins as cytotoxic drugs |
| 07/17/2003 | US20030133931 Combining a putative modulator compound of mammalian histamine H4 receptor protein activity with mammalian histamine H4 receptor protein and a known histamine receptor H4 ligand, measuring the effect of the modulator on the protein |
| 07/17/2003 | US20030133929 Draining blood from the animal, separating blood cells from plasma, contacting plasma with a solvent in which lipids are soluble, separating plasma to reintroduce it into the animal, separating dissolved lipids |
| 07/17/2003 | US20030133925 Monobactam compositions and methods of use thereof |
| 07/17/2003 | US20030133920 Koji molds for preparing cholesterol lowering products |
| 07/17/2003 | US20030133911 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 07/17/2003 | US20030133889 Treating skin and/or mucous membrane by applying an aqueous solution of ascorbic acid or a derivative stabilized by the polymer; oxidation resistance; sunscreen agents; combatting pollution, sunburn; free radical scavengers; skin tone |
| 07/17/2003 | CA2473106A1 Pravastatin pharmaceutical formulations and methods of their use |
| 07/17/2003 | CA2472893A1 Cancer treatment |
| 07/17/2003 | CA2472647A1 Mammal prolactin variants |
| 07/17/2003 | CA2472585A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | CA2472331A1 Process and intermediates for pyridazinone antidiabetic agents |
| 07/17/2003 | CA2472198A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 07/17/2003 | CA2472165A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | CA2472154A1 Use of antibodies against the muc18 antigen |
| 07/17/2003 | CA2472151A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 07/17/2003 | CA2472118A1 Pak5-related compositions and methods |
| 07/17/2003 | CA2472111A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | CA2471957A1 Cyclic tetrapeptide compound and use thereof |
| 07/17/2003 | CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | CA2471936A1 Methods for using anti-muc18 antibodies |
| 07/17/2003 | CA2471932A1 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 07/17/2003 | CA2471885A1 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | CA2471880A1 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | CA2471846A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 07/17/2003 | CA2471760A1 Preventives/remedies for urinary disturbance |
| 07/17/2003 | CA2471754A1 Androgen receptor antagonist |
| 07/17/2003 | CA2471509A1 Combinations comprising epothilones and anti-metabolites |
| 07/17/2003 | CA2471504A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 07/17/2003 | CA2471490A1 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders |
| 07/17/2003 | CA2471432A1 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 07/17/2003 | CA2471214A1 The use of histamine h4 receptor antagonist for the treatment of inflammatory response |
| 07/17/2003 | CA2471204A1 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | CA2470411A1 System for monitoring bacterial tumor treatment |
| 07/17/2003 | CA2470164A1 New crystalline forms of meloxicam and processes for their preparation and interconversion. |
| 07/17/2003 | CA2469480A1 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/17/2003 | CA2469162A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases |
| 07/17/2003 | CA2468888A1 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 07/16/2003 | EP1327452A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 07/16/2003 | EP1327448A1 Homeostasis-maintaining agents |
| 07/16/2003 | EP1326986A2 Regulation of human sphingosine kinase-like protein |
| 07/16/2003 | EP1326978A2 Hematopoietin receptors hpr1 and hpr2 |
| 07/16/2003 | EP1326971A2 Proteins and nucleic acids encoding same |
| 07/16/2003 | EP1326967A2 Novel aggrecanase molecules |
| 07/16/2003 | EP1326896A2 Human anti-cd40 antibodies |
| 07/16/2003 | EP1326894A2 Novel tumor-associated marker |
| 07/16/2003 | EP1326893A2 Plasma fraction containing bikunin, method for the production thereof and use of the same |
| 07/16/2003 | EP1326891A1 Gene encoding a human g-protein coupled receptor and its use |
| 07/16/2003 | EP1326876A2 Anhydro sugar derivatives of indolocarbazoles |
| 07/16/2003 | EP1326875A2 Tumor proliferation inhibitors |
| 07/16/2003 | EP1326874A2 Topoisomerase inhibitors |
| 07/16/2003 | EP1326869A1 Pyrrole-condensed morphinoid derivatives |
| 07/16/2003 | EP1326868A1 Morphinoid derivatives as delta-opioid agonists and antagonists |
| 07/16/2003 | EP1326867A2 Bridged piperazine derivatives |
| 07/16/2003 | EP1326864A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 07/16/2003 | EP1326863A2 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 07/16/2003 | EP1326862A1 Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
| 07/16/2003 | EP1326857A2 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonists |
| 07/16/2003 | EP1326856A1 Pyridine derivatives with ikb-kinase (ikk-beta) inhibiting activity |
| 07/16/2003 | EP1326851A1 Substituted dipeptides as growth hormone secretagogues |
| 07/16/2003 | EP1326848A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 07/16/2003 | EP1326847A1 (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use |
| 07/16/2003 | EP1326840A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/16/2003 | EP1326838A1 Novel crystalline forms of a factor xa inhibitor |
| 07/16/2003 | EP1326835A1 Benzamide compounds as apo b secretion inhibitors |
| 07/16/2003 | EP1326834A2 2-substituted heterocyclic compounds |
| 07/16/2003 | EP1326833A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/16/2003 | EP1326828A1 Beta-amino acid derivatives as integrin receptor antagonists |
| 07/16/2003 | EP1326825A2 Compounds and compositions for delivering active agents |
| 07/16/2003 | EP1326822A2 Ketone compounds and compositions for cholesterol management and related uses |
| 07/16/2003 | EP1326642A2 Catecholamine pharmaceutical compositions and methods |
| 07/16/2003 | EP1326632A2 Agents for the treatment of viral infections |
| 07/16/2003 | EP1326631A1 Methods for treating endocrine disorders |
| 07/16/2003 | EP1326627A1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 07/16/2003 | EP1326619A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 07/16/2003 | EP1326618A2 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 07/16/2003 | EP1326617A1 Use of antiprogestins for the induction of apoptosis in a cell |
| 07/16/2003 | EP1326613A1 Use of substituted imidazo 1,2-a]pyridine-, imidazo 1,2-a]pyrimidine and imidazo 1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting medicaments |
| 07/16/2003 | EP1326611A1 Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| 07/16/2003 | EP1326610A2 Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| 07/16/2003 | EP1326607A1 Pharmaceutical compositions containing oxapenem-3-carboxilic acids |
| 07/16/2003 | EP1326606A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/16/2003 | EP1326605A1 Methods for inhibiting proliferation and inducing apoptosis in cancer cells |
| 07/16/2003 | EP1326604A2 Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
| 07/16/2003 | EP1326603A1 Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| 07/16/2003 | EP1326597A2 Methods for modulating bladder function |
| 07/16/2003 | EP1326593A1 ESTROGEN RECEPTOR-$g(b) LIGANDS |
| 07/16/2003 | EP1326591A2 Combination of statins and sorbitol dehydrogenase inhibitors |
| 07/16/2003 | EP1326586A1 New pharmaceutical compositions containing epinastine and pseudoephedrine |
| 07/16/2003 | EP1326585A2 Method for producing powdery formulations |